Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Long conserved protein | 0.0959 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0959 | 1 | 0.5 |
Mycobacterium ulcerans | transglutaminase family protein | 0.0959 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0959 | 1 | 0.5 |
Echinococcus multilocularis | Transglutaminase | 0.0959 | 1 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0959 | 1 | 0.5 |
Mycobacterium leprae | Conserved hypothetical protein | 0.0959 | 1 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0959 | 1 | 0.5 |
Mycobacterium ulcerans | putative transglutaminase-like protein | 0.0959 | 1 | 0.5 |
Trichomonas vaginalis | peptide N-glycanase, putative | 0.0959 | 1 | 0.5 |
Mycobacterium leprae | Conserved hypothetical protein | 0.0959 | 1 | 0.5 |
Mycobacterium tuberculosis | Conserved protein | 0.0959 | 1 | 0.5 |
Onchocerca volvulus | 0.0959 | 1 | 1 | |
Mycobacterium ulcerans | hypothetical protein | 0.0959 | 1 | 0.5 |
Giardia lamblia | Transglutaminase/protease, putative | 0.0959 | 1 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0959 | 1 | 0.5 |
Mycobacterium tuberculosis | Hypothetical protein | 0.0959 | 1 | 0.5 |
Echinococcus granulosus | Transglutaminase | 0.0959 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | Antifungal activity against Cryptococcus neoformans assessed as growth inhibition at 200 ug/mL after 72 to 96 hr by two-fold serial dilution method | ChEMBL. | No reference | |
GI (functional) | Antibacterial activity against Escherichia coli assessed as growth inhibition at 200 ug/mL after 24 hr by two-fold serial dilution method | ChEMBL. | No reference | |
MIC (functional) | = 200 ug ml-1 | Antifungal activity against Candida albicans after 72 to 96 hr by two-fold serial dilution method | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.